$1,719.38 general Payment -- AstraZeneca to Dr. Charles Baker

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

AstraZeneca made a $1.7K general payment to Charles Baker, a Cardiology specialist in Springfield, IL. The payment was associated with Skyrizi. The payment of $1719.38 to Dr. Charles Baker from AstraZeneca is for services other than consulting. This payment is associated with the drug Skyrizi, a treatment relevant to Cardiology. The payment was made on July 10, 2024, and recorded under payment ID OP-MNGW7GM5-DHVGOC.

Patient Guidance: What This Payment Means for You

If you are a patient prescribed Skyrizi, this payment indicates your cardiologist may receive compensation for services related to this medication. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

For cardiologists, payments for services other than consulting can vary widely; this specific payment for services related to Skyrizi falls within a moderate range of typical compensation.

Regulatory Context: Sunshine Act Requirements

This payment is reported under the Physician Payments Sunshine Act, requiring transparency in financial relationships between drug manufacturers and healthcare providers.

Related Topics

This payment is related to the following healthcare transparency topics:

• cardiology
• astrazeneca
• skyrizi
• physician-payment
• cms-open-payments
• pharmaceutical-industry

Understanding general Payments

general payments are one of several categories of financial transfers from pharmaceutical and medical device companies to physicians that must be reported under the Sunshine Act. Understanding the type and context of a payment is important for evaluating its significance. Not all payments are equal -- a research grant has very different implications than a promotional speaking fee.

Frequently Asked Questions About This Payment

What was this $1.7K payment for?

This was a general payment of $1.7K from AstraZeneca to Charles Baker, categorized as "Compensation for services other than consulting". It was associated with Skyrizi. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Charles Baker accept pharmaceutical money?

Yes, Charles Baker received this $1.7K payment from AstraZeneca. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Charles Baker's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this general payment?

A general payment of $1.7K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Cardiology?

To compare this payment against Cardiology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Cardiology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Charles Baker's relationship with AstraZeneca?

The payment is categorized as 'general' and specifically for 'Compensation for services other than consulting'. This $1.7K general payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Cardiology?

Dr. Baker's specialty is Cardiology, and the payment is linked to Skyrizi.

What should patients do after learning about this payment?

If you are a patient prescribed Skyrizi, this payment indicates your cardiologist may receive compensation for services related to this medication.

What else should I know about this general payment?

The payment occurred in Springfield, IL.

Related Reports

• View Dr. Charles Baker's full payment report
• AstraZeneca full spending report
• Browse all Cardiology payments
• Browse all payments in Illinois
• Search for other payments